3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Carcinoma, Neuroendocrine
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Fluorodeoxyglucose F18
3
Doxorubicin
3
Cyclophosphamide
3
surufatinib
2
fludarabine
2
entrectinib
2
Radiotherapy
2
Nivolumab
2
Ifosfamide
2
Filgrastim
2
Drug Therapy
2
Cisplatin
2
tivozanib
1
tislelizumab
1
tipifarnib
1
selpercatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
pembrolizumab
1
milademetan
1
ganitumab
1
fludarabine phosphate
1
entinostat
1
dostarlimab
1
conatumumab
1
cixutumumab
1
cabozantinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
dostarlimab
×
Endocrine
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled